表紙
市場調查報告書

全球人工心臟市場 2019年∼2023年

Global Artificial Heart Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 851222
出版日期 內容資訊 英文 117 Pages
訂單完成後即時交付
價格
Back to Top
全球人工心臟市場 2019年∼2023年 Global Artificial Heart Market 2019-2023
出版日期: 2019年05月14日內容資訊: 英文 117 Pages
簡介

全球人工心臟市場,由於輔助人工心臟(VAD)技術的進步預計促進成長。下一代輔助人工心臟(VAD),裝載直接流量檢測和參數遠隔監視等新技術。透過人工心臟的利用,患者存活率及生活品質(QOL)大幅度上升。還有人工心臟的耐用性也提高,使用相關的併發症的發生率也降低。全球人工心臟市場至2023年預計將以約9%的年複合成長率發展。

本報告提供全球人工心臟市場調查,市場概要,各產品、各地區的市場規模的變化與預測,市場成長要素及課題分析,競爭情形,主要企業的簡介等全面性資訊。

第1章 摘要整理

第2章 報告範圍

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模
  • 市場規模及預測

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 市場比較:各產品
  • 輔助人工心臟(VAD)
  • 完全置換型人工心臟(TAH)
  • 市場機會:各產品

第7章 客戶形勢

第8章 地區形勢

  • 市場區隔:各地區
  • 市場比較:各地區
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 市場牽引國
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 對於TAH的開發的臨床試驗
  • 血液非接觸式VAD的開發
  • 策略性收購

第12章 業者情勢

  • 概要
  • 創造性破壞狀況

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Abbott
  • Abiomed Inc.
  • Medtronic
  • ReliantHeart Inc.
  • SynCardia Systems LLC

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31298

About this market

Advances in VAD technology will be a key factor driving the growth of the market. The newer generation VADs use several new technologies such as direct flow measurement and remote parameter monitoring and are capable of a wide range of flow for full and/or partial support. They have significantly enhanced survival rates, better quality of life, and device durability with reduced device-related complication rates. Such technological advances and product launches are expected to increase the demand for VADs, which in turn, drives the market. Technavio' s analysts have predicted that the artificial heart m market will register a CAGR of almost 9% by 2023.

Market Overview

Increasing prevalence of HF and associated risk factors

The prevalence of HF has been steadily increasing in developing as well as developed countries. In Europe, HF affects 20,000 out of one million people in the general population. The prevalence of HF in western countries is estimated to be around 10,000 to 20,000 out of one million individuals, and the average incidence is around 7,500 per million persons each year. Furthermore, the number of hospital admissions due to HF has also been steadily increasing in several countries. This, in turn, will increase the demand for artificial hearts.

High cost of artificial hearts

The high cost of VADs and TAHs is restricting their widespread adoption in developed as well as developing countries. Vendors offering artificial hearts can charge high prices in part due to structural barriers to competition such as the complex and costly regulatory approval process, and patent protection. These barriers hinder the import of artificial hearts that might compete with domestically manufactured devices and reduce the prices. Hence, the high cost of artificial hearts and procedures are hampering the growth of the global artificial heart market.

For the detailed list of factors that will drive and challenge the growth of the artificial heart market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be highly concentrated. The presence of few companies including ReliantHeart Inc. and SynCardia Systems LLC makes competitive environment is quite intense. Factors such as the advances in VAD and increasing prevalence of HF and associated risk factors, will provide considerable growth opportunities to artificial heart manufactures. Abbott, Abiomed Inc., Medtronic, ReliantHeart Inc., and SynCardia Systems LLC are some of the major companies covered in this report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • VAD - Market size and forecast 2018-2023
  • TAH - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Clinical trials for the development of TAHs
  • Focus on development of non-blood-contacting VADs
  • Strategic acquisitions

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Abbott
  • Abiomed Inc.
  • Medtronic
  • ReliantHeart Inc.
  • SynCardia Systems LLC

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global medical devices market
  • Exhibit 02: Segments of global medical devices market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Product - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by product
  • Exhibit 19: VAD - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: VAD - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: TAH - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: TAH - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Market opportunity by product
  • Exhibit 24: Customer landscape
  • Exhibit 25: Market share by geography 2018-2023 (%)
  • Exhibit 26: Geographic comparison
  • Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Key leading countries
  • Exhibit 36: Market opportunity
  • Exhibit 37: Impact of drivers and challenges
  • Exhibit 38: Vendor landscape
  • Exhibit 39: Landscape disruption
  • Exhibit 40: Vendors covered
  • Exhibit 41: Vendor classification
  • Exhibit 42: Market positioning of vendors
  • Exhibit 43: Abbott - Vendor overview
  • Exhibit 44: Abbott - Business segments
  • Exhibit 45: Abbott - Organizational developments
  • Exhibit 46: Abbott - Geographic focus
  • Exhibit 47: Abbott - Segment focus
  • Exhibit 48: Abbott - Key offerings
  • Exhibit 49: Abbott - Key customers
  • Exhibit 50: Abiomed Inc. - Vendor overview
  • Exhibit 51: Abiomed Inc. - Product segments
  • Exhibit 52: Abiomed Inc. - Organizational developments
  • Exhibit 53: Abiomed Inc. - Segment focus
  • Exhibit 54: Abiomed Inc. - Key offerings
  • Exhibit 55: Abiomed Inc. - Key customers
  • Exhibit 56: Medtronic - Vendor overview
  • Exhibit 57: Medtronic - Business segments
  • Exhibit 58: Medtronic - Organizational developments
  • Exhibit 59: Medtronic - Geographic focus
  • Exhibit 60: Medtronic - Segment focus
  • Exhibit 61: Medtronic - Key offerings
  • Exhibit 62: Medtronic - Key customers
  • Exhibit 63: ReliantHeart Inc. - Vendor overview
  • Exhibit 64: ReliantHeart Inc. - Product segments
  • Exhibit 65: ReliantHeart Inc. - Organizational developments
  • Exhibit 66: ReliantHeart Inc. - Key offerings
  • Exhibit 67: ReliantHeart Inc. - Key customers
  • Exhibit 68: SynCardia Systems LLC - Vendor overview
  • Exhibit 69: SynCardia Systems LLC - Product segments
  • Exhibit 70: SynCardia Systems LLC - Organizational developments
  • Exhibit 71: SynCardia Systems LLC - Key offerings
  • Exhibit 72: SynCardia Systems LLC - Key customers
  • Exhibit 73: Validation techniques employed for market sizing
  • Exhibit 74: Definition of market positioning of vendors
Back to Top